TickerFacts.

Royalty Pharma plc (RPRX): Operating Income

Annual figures by period end, from SEC filings.

$1.56B
Year ended 2025-12-31
$1.51B
Trailing 12 months to 2026-06-30
+71.9%
3-year compound annual growth
-0.5%
5-year compound annual growth
$2.62B2018-12-31: $1.36B2019-12-31: $2.62B2020-12-31: $1.60B2021-12-31: $1.43B2022-12-31: $307.06M2023-12-31: $1.49B2024-12-31: $1.29B2025-12-31: $1.56B$1.56B
2018-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31$1.56B+20.7%2026-02-11, From 2025-01-01
2024-12-31$1.29B-13.4%2026-02-11, From 2024-01-01
2023-12-31$1.49B+385.9%2026-02-11, From 2023-01-01
2022-12-31$307.06M-78.5%2025-02-12, From 2022-01-01
2021-12-31$1.43B-10.3%2024-02-15, From 2021-01-01
2020-12-31$1.60B-39.2%2023-02-15, From 2020-01-01
2019-12-31$2.62B+92.3%2022-02-15, From 2019-01-01
2018-12-31$1.36Bn/a2021-02-24, From 2018-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Royalty Pharma plc (RPRX)2025-12-31$1.56B+20.7%
Sarepta Therapeutics, Inc. (SRPT)2025-12-31-$699.78Mn/m
Amneal Pharmaceuticals, Inc. (AMRX)2025-12-31$394.10M+58.1%
United Therapeutics Corp (UTHR)2025-12-31$1.49B+8.4%
BioMarin Pharmaceutical Inc (BMRN)2025-12-31$409.48M-15.4%
PTC Therapeutics, Inc. (PTCT)2025-12-31$866.93Mn/m
Alnylam Pharmaceuticals, Inc. (ALNY)2025-12-31$501.58Mn/m
Phibro Animal Health Corp (PAHC)2026-06-30$194.40M+76.0%
Alkermes plc. (ALKS)2025-12-31$253.96M-39.6%

Compare RPRX, SRPT, AMRX, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗